SPEAKERS

Tariq Arif, J.D., M.B.A.

Tariq Arif is the Business Development Officer in UCLA’s Technology Development Group.  In this role, Mr. Arif oversees marketing, patenting, and licensing of UCLA’s Life Science Technology portfolio, spanning immuno-oncology, immunology, infectious diseases, neurosciences and regenerative medicine.  He currently manages UCLA’s alliance with the Parker Institute for Cancer Immunotherapy.

Mr. Arif has 15 years of technology transfer experience, having handled licensing and technology transfer at Partners HealthCare Innovation in Boston, the NIH-National Cancer Institute in Maryland, Atara Biotherapeutics, and the Center for Innovation at Children’s Hospital Los Angeles, among others. He received his M.B.A. from Northwestern University Kellogg School of Management, his J.D./L.L.M. from University of New Hampshire – Pierce Law, and his Master’s of Science in Biochemistry and Molecular Biology from Georgetown University.

Arka Chatterjee, J.D.

Arka Chatterjee is Lead Intellectual Property Counsel at Natera, Inc., where he advises on litigation and risk management and intellectual property strategy.  His work spans a wide gamut of IP activities including patent prosecution and litigation, trademark registration and enforcement, deal support, and day-to-day advising of both R&D and executive leadership.

Prior to joining Natera, Mr. Chatterjee worked at several elite law firms on intellectual property and antitrust matters relating to a variety of technology areas.  He obtained his J.D. from Columbia Law School.  He also worked as a scientist researching the efficacy of small-molecule therapeutics upon numerous cancers and autoimmune diseases.

Sandra Haberny, J.D., Ph.D.

Dr. Sandra Haberny is a Partner in Quinn Emanuel’s Los Angeles office.  She has an extensive patent litigation and trade secret practice with an emphasis in the life sciences.  Dr. Haberny advises on due diligence and pre-litigation strategy, and she has litigated, advised clients, and tried cases in a range of complex technologies including molecular diagnostics, DNA sequencing, CRISPR, monoclonal antibody therapies, CAR-T, RNA interference, small molecule compounds and drugs, among many others.

Dr. Haberny is admitted to practice before the United States Patent and Trademark Office, and has experience prosecuting patents, conducting inter partes review and post grant review proceedings, and counseling clients on patent portfolio development and enforcement strategy.  Prior to her legal career, she received her M.S. and Ph.D. degrees in Molecular Pharmacology from the New York University School of Medicine.

SPONSORS

Diamond Sponsors

Silver Sponsors

Questions? Contact the LAIPLA office at office@laipla.net or call 323-285-1654.

Sponsorship? See LAIPLA Sponsorship Opportunities for this event and others.